SuperworthRxSight RXST
- Market cap
- $208.8M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 1.6×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $127.6M
- −13% on a year ago
- Net margin
- −36.8%
- Free cash flow yield
- −13.0%
RxSight trades at 1.6× sales. Its trailing earnings are negative, so it has no PE. Revenue was $127.6M over the last twelve months, down 13% on a year earlier with a −37% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $22.2M+76% | $28.6M+78% | $29.5M+69% | $34.9M+68% | $35.3M+59% | $40.2M+41% | $37.9M+28% | $33.6M−4% | $30.3M−14% | $32.6M−19% | $30.9M−19% | $33.7M+0% | |
| Cost of revenue | $8.5M+17% | $10.9M+26% | $8.8M+24% | $10.6M+21% | $10.1M+19% | $11.4M+5% | $9.6M+8% | $8.4M−21% | $6.1M−39% | $7.3M−36% | $7.4M−23% | n/a |
| Gross profit | $13.7M+156% | $17.7M+138% | $20.7M+100% | $24.3M+102% | $25.2M+84% | $28.8M+63% | $28.3M+37% | $25.2M+4% | $24.2M−4% | $25.3M−12% | $23.5M−17% | n/a |
| R&D | $7.1M+11% | $7.3M+10% | $8M+11% | $8.3M+12% | $8.8M+25% | $9.2M+25% | $10.4M+29% | $10.2M+23% | $9.1M+3% | $8.9M−3% | $9.5M−9% | $9.2M−10% |
| SG&A | $19.1M+28% | $21.2M+35% | $23.3M+44% | $24.3M+33% | $25.6M+34% | $28.2M+33% | $28.6M+23% | $29M+19% | $27.3M+7% | $27.7M−2% | $31.9M+11% | $30.4M+5% |
| −$12.5M−22% | −$10.9M−28% | −$10.7M−19% | −$8.3M−39% | −$9.2M−26% | −$8.6M−21% | −$10.7M+0% | −$14M+68% | −$12.2M+32% | −$11.3M+31% | −$17.8M+67% | −$13.8M−2% | |
| Interest expense | $230K−82% | $4K−100% | $6K−100% | $6K−100% | $5K−98% | $5K+25% | $6K+0% | $5K−17% | $4K−20% | $5K+0% | $3K−50% | $3K−40% |
| Pre-tax income | −$12.4M−26% | −$9.2M−41% | −$9.1M−31% | −$6.1M−56% | −$6.3M−49% | −$5.9M−36% | −$8.2M−10% | −$11.8M+94% | −$9.8M+55% | −$9.1M+54% | −$15.9M+94% | −$12M+2% |
| $12K | −$18K | $9K | $16K−39% | $13K+8% | $12K | $18K+100% | $32K+100% | $10K−23% | $5K−58% | $6K−67% | $88K+175% | |
| Net income | −$12.4M−26% | −$9.2M−41% | −$9.1M−31% | −$6.1M−56% | −$6.3M−49% | −$5.9M−35% | −$8.2M−10% | −$11.8M+94% | −$9.8M+55% | −$9.2M+54% | −$15.9M+94% | −$12.1M+3% |
| −$0.35−43% | −$0.26−54% | −$0.25−41% | −$0.16−60% | −$0.16−54% | −$0.15−42% | −$0.20−20% | −$0.29+81% | −$0.24+50% | −$0.22+47% | −$0.38+90% | −$0.29+0% | |
| 35.7M+29% | 36M+29% | 36.8M+17% | 38.5M+12% | 39.8M+12% | 40.4M+12% | 40.5M+10% | 40.7M+6% | 41M+3% | 41.2M+2% | 41.3M+2% | 41.5M+2% |
Revenue: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
R&D: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
SG&A: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Operating income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Income tax: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Net income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
EPS, diluted: 5 periods, Q4 FY21 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 5 periods, Q4 FY21 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest RxSight's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| RXSTRxSight | $208.8M | n/m | n/a | 1.6× | −13% | −36.8% | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| UTMDUtah Medical Products | $236.3M | 22.6× | 20.9× | 6.5× | −7% | 29.0% | |
| INFUInfuSystem | $277.6M | 34.0× | 43.5× | 1.9× | +2% | 6.0% | |
| EMBCEmbecta | $380.2M | 4.6× | 11.7× | 0.4× | −8% | 8.6% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| TCMDTactile Systems Technology | $535.5M | 21.9× | 62.9× | 1.5× | +17% | 7.1% | |
| MDXGMimedx | $569.9M | 97.8× | 21.1× | 1.6× | −2% | 1.8% | |
| MOVMovado | $701.9M | 17.5× | 13.3× | 1.0× | +5% | 6.0% | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| IRMDIradimed | $1.1B | 47.9× | 41.4× | 12.7× | +11% | 26.7% | |
| Peer median | $328.9M | 19.7× | 18.7× | 1.6× | +5% | 6.9% |
More on RxSight
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .